Clinical trial
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
NCT00281021 · University of Louisville, Other · Terminated
Key facts
| NCT number | NCT00281021 |
|---|---|
| Title | Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | University of Louisville, Other |
| Collaborators | James Graham Brown Cancer Center |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | Erlotinib plus Digoxin |
| Enrollment | 26 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jan 24, 2006 |
| Last update posted | Mar 29, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: